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 36 
BOX: RESEARCH IN CONTEXT 37 
Evidence before this study 38 
Evidence from previous trials of biodegradable-polymer stents is conflicting. The BIOFLOW-II, 39 
BIOSCIENCE, and BIORESORT trials showed non-inferiority for biodegradable-polymer sirolimus-40 
eluting stents compared with durable-polymer drug-eluting stents with regards to primary 41 
angiographic or composite clinical endpoints at 9 months or 1 year. By contrast, the BIOFLOW V trial 42 
found a lower incidence of target lesion failure at 1 year in patients treated with biodegradable-43 
polymer sirolimus-eluting stents than in those treated with durable-polymer everolimus-eluting 44 
stents. We searched PubMed, the Cochrane Library Central Register of Controlled Trials, and Embase 45 
up to June 15, 2018, for randomised trials comparing ultrathin-strut, biodegradable-polymer, 46 
sirolimus-eluting stents with durable-polymer everolimus-eluting stents. We searched without 47 
language restrictions and using the search algorithm (biodegradable* OR bioresorbable*) AND 48 
sirolimus* AND stent* AND random*. We identified four trials, in addition to BIOSCIENCE, that 49 
fulfilled the inclusion criteria. In a meta-analysis of these trials, we found that there was no 50 
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difference between ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents and durable-51 
polymer everolimus-eluting stents in the composite outcome of target lesion failure at the longest 52 
available follow-up. By contrast, ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents 53 
reduced risk of myocardial infarction by 23% (risk ratio 0·77, 95% CI 0·63–0·95) compared with 54 
durable-polymer everolimus-eluting stents. 55 
 56 
Added value of this study 57 
To our knowledge, this study is the first to assess long-term efficacy and safety outcomes of an 58 
ultrathin-strut, biodegradable-polymer, sirolimus-eluting stent, beyond the time of complete 59 
degradation of the polymer, in an adequately powered randomised trial with the best-in-class 60 
durable-polymer everolimus-eluting stent as a comparator. We found no difference between stents 61 
in the composite outcome of target lesion failure at 5 years (rate ratio 1·07, 95% CI 0·88–1·31). 62 
Additionally, we observed no difference in incidence of myocardial infarction between 63 
biodegradable-polymer sirolimus-eluting stents and durable-polymer everolimus-eluting stents at 5 64 
years (0·85, 0·65–1·28). This study adds to existing clinical evidence on the newest generation of 65 
drug-eluting stents that combine biodegradable polymers with ultrathin-stent platforms. 66 
 67 
Implication of all the available evidence 68 
Ultrathin-strut, biodegradable-polymer, sirolimus-elutings stents have similar safety and efficacy to 69 
durable-polymer everolimus-eluting stents during long-term follow-up. 70 
  71 
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SUMMARY 72 
Background 73 
Drug-eluting stents combining an ultrathin cobalt-chromium stent platform with a biodegradable 74 
polymer eluting sirolimus have been shown to be non-inferior or superior to thin-strut, durable-75 
polymer, everolimus-eluting stents in terms of 1 year safety and efficacy outcomes. 76 
Methods 77 
In the randomised, single-blind, multicentre, non-inferiority BIOSCIENCE trial, we compared 78 
biodegradable-polymer sirolimus-eluting stents with durable-polymer everolimus-eluting stents in 79 
patients with chronic stable coronary artery disease or acute coronary syndromes. Here, we assess 80 
the final 5-year clinical outcomes of BIOSCIENCE with regards to the primary clinical outcome of 81 
target lesion failure, which was a composite of cardiac death, target vessel myocardial infarction, 82 
and clinically indicated target lesion revascularisation. The primary analysis was done by intention to 83 
treat. The BIOSCIENCE trial is registered with ClinicalTrials.gov, number NCT01443104. 84 
Findings 85 
2008 (95%) of 2119 patients recruited between March 1, 2012, and May 31, 2013, completed 5 86 
years of followup. Target lesion failure occurred in 198 patients (cumulative incidence 20·2%) 87 
treated with biodegradable-polymer sirolimus-eluting stents and in 189 patients (18·8%) treated 88 
with durable-polymer everolimus-eluting stents (rate ratio [RR] 1·07, 95% CI 0·88–1·31; p=0·487). 89 
All-cause mortality was significantly higher in patients treated with biodegradable-polymer 90 
sirolimus-eluting stents than in those treated with durable-polymer everolimus-eluting stents (14·1% 91 
vs 10·3%; RR 1·36, 95% CI 1·06–1·75; p=0·017), driven by a difference in non-cardiovascular deaths. 92 
We observed no difference between groups in cumulative incidence of definite stent thrombosis at 5 93 
years (1·6% in both groups; 1·02, 0·51–2·05; p=0·950). 94 
Interpretation 95 
5-year risk of target lesion failure among all-comer patients undergoing percutaneous coronary 96 
intervention is similar after implantation of ultrathin-strut, biodegradable-polymer, sirolimus-eluting 97 
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stents or thin-strut, durable-polymer, everolimus-eluting stents. Higher incidences of all-cause and 98 
non-cardiovascular mortality in patients treated with biodegradable-polymer stents eluting sirolimus 99 
than in those treated with durable-polymer stents eluting everolimus warrant careful observation in 100 
ongoing clinical trials. 101 
 102 
INTRODUCTION 103 
Biodegradable-polymer stents are associated with improved vascular healing after implantation of 104 
drug-eluting stents and reduced risk of very late stent thrombosis compared with earlier generations 105 
of drug-eluting stents.1,2 Newer-generation, biodegradable-polymer, drug-eluting stents differ from 106 
each other in polymer degradation times (ranging from 3 months to >1 year), drug-release kinetics, 107 
and strut thickness.3–7 108 
Newer-generation drug-eluting stents combining ultrathin-strut cobalt-chromium platforms with 109 
biodegradable polymers eluting sirolimus have been associated with a reduced risk of definite stent 110 
thrombosis compared with thick-strut, stainless steel, biodegradable-polymer, drug-eluting stents,8 111 
and were non-inferior to thinstrut, durable-polymer, drug-eluting stents with regards to composites 112 
of clinical endpoints at 1 year in two randomised controlled trials.5,9 More recently, the randomised 113 
controlled BIOFLOW V trial10 reported a lower incidence of target lesion failure at 1 year, driven by 114 
a lower incidence of myocardial infarction, in patients treated with biodegradable-polymer 115 
sirolimus-eluting stents than in those treated with durable-polymer everolimus-eluting stents. 116 
The rationale for the use of biodegradable polymers is to mitigate a polymer-induced chronic 117 
inflammatory response, potentially translating into late clinical adverse events. The benefit of 118 
biodegradable polymers in newer-generation drug-eluting stents might therefore be expected to 119 
take effect beyond the degradation time of the polymer. Long-term clinical outcome data from 120 
randomised controlled trials investigating newer-generation, biodegradable-polymer, sirolimus-121 
eluting stents have not yet been reported. Here, we report the 5-year outcomes of the BIOSCIENCE 122 
randomised controlled trial comparing efficacy and safety outcomes of an ultrathin-strut, 123 
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biodegradable-polymer, drug-eluting stent with those of a durable-polymer everolimus-eluting 124 
stent. 125 
 126 
METHODS 127 
Study design and patients 128 
The BIOSCIENCE trial was an investigator-initiated, single-blind, multicentre, randomised, non-129 
inferiority trial. Eligible patients had coronary artery disease and at least one lesion with more than 130 
50% diameter de-novo stenosis or restenosis in a native coronary artery or a bypass graft. 131 
Additionally, patients had to present with stable coronary artery disease or acute coronary 132 
syndromes. 133 
The rationale of the trial, as well as details of randomisation, masking, and data management, have 134 
been described previously.11 Briefly, patients were randomly assigned in a 1:1 ratio to 135 
biodegradable-polymer sirolimus-eluting stents or to durable-polymer everolimus-eluting stents in 136 
nine centres in Switzerland. The experimental stent (Orsiro; Biotronik AG, Bülach, Switzerland) 137 
consisted of an ultrathin (60 μm for stent diameters ≤3·0 mm, 80 μm for stent diameters >3·0 mm) 138 
cobalt-chromium L605 metallic carrier covered with an amorphous, hydrogen-rich, silicon-carbide 139 
layer (PROBIO) and an asymmetric biodegradable poly-L-lactic acid polymer that released sirolimus 140 
at a dose of 1·4 μg per mm² stent surface over a period of 12–14 weeks. The polymer matrix 141 
degraded in 12–24 months.12 The control stent (Xience Prime/Xpedition stent; Abbott Vascular, 142 
Abbott Park, IL, USA) consisted of a thin (81 μm) L605 cobalt-chromium platform that released 143 
everolimus from a durable polymer (poly-n-butyl-methacrylate and co-polymer of vinylidine fluoride 144 
and hexafluoropropylene). 145 
The study was approved by the institutional ethics committees of all participating sites and complied 146 
with the Declaration of Helsinki. All patients provided written, informed consent for participation. 147 
The trial is registered with ClinicalTrials.gov, number NCT01443104. The non-inferiority test was 148 
reported previously.5 149 
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Outcomes 150 
Patients were followed up at 30 days, 1 year, 2 years, and 5 years in a standardised telephone 151 
interview or during a visit to the clinic. The primary endpoint, target lesion failure, was a composite 152 
of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion 153 
revascularisation within 12 months. Cardiac death was defined as any death due to immediate 154 
cardiac cause, death related to the procedure, unwitnessed death, and death of unknown cause. 155 
Myocardial infarction was differentiated according to the electrocardiographic criteria of the 156 
Minnesota code manual into Q-wave and non-Q-wave myocardial infarction. 13 Spontaneous 157 
myocardial infarction was defined as a characteristic rise and fall of creatinine kinase-MB fraction or 158 
troponin in the presence of at least one of ischaemic symptoms, new pathological Q waves, 159 
ischaemic electrocardiographic changes, and pathological evidence of acute myocardial infarction.14 160 
Target lesion revascularisation was defined as any repeat percutaneous or surgical intervention due 161 
to a stenosis or occlusion within the stent or within the 5 mm borders proximal or distal to the stent. 162 
Target vessel revascularisation was defined as any revascularisation within the entire major coronary 163 
vessels proximal or distal to a target lesion including upstream and downstream side branches and 164 
the target lesion itself. Stent thrombosis was categorised according to the definitions provided by 165 
the Academic Research Consortium.15 All definitions have been described previously. 11 Any death, 166 
reinfarction, revascularisation, stent thrombosis, cerebrovascular accident, or bleeding event was 167 
independently adjudicated by a clinical events committee masked to treatment assignment. 168 
 169 
Statistical analysis 170 
We compared patients’ medications and anginal status at each follow-up visit using Fisher’s exact 171 
test. The Mantel-Cox method was used to calculate rate ratios (RRs), with 95% CIs and p values 172 
calculated with the log-rank test. We used time to first event for each outcome, and report numbers 173 
of patients and Kaplan-Meier estimates of cumulative incidence. A landmark analysis was done by 174 
setting as a landmark at 1 year the p value of the interaction for effect modification by period. We 175 
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did stratified analyses of the primary endpoint for several prespecified subgroups: diabetes, acute 176 
coronary syndrome, ST-segment elevation myocardial infarction (STEMI), and off-label use. Off-label 177 
was defined as patients with STEMI, any lesion length greater than 30 mm, any restenotic lesion, any 178 
totally occluded lesion, or any lesion within a saphenous vein graft. We also did post-hoc subgroup 179 
analyses of small vessels (defined as stent diameter in any lesion ≤3 mm), in-stent restenosis, long 180 
lesions (defined as a total stent length in any lesion of ≥20 mm), multivessel percutaneous coronary 181 
intervention, sex, age, body-mass index, and renal failure (defined as creatinine-estimated 182 
glomerular filtration rate <60 mL/min using the Modification of Diet in Renal Disease16 formula). To 183 
identify interactions between treatment group and each of these subgroups in the effect size, we did 184 
approximate Mantel-Haenszel χ² tests for effect modification. All patients who were randomly 185 
assigned and provided written, informed consent were included and analysed according to the 186 
intention-to-treat principle. Statistical analyses were done with Stata 14.2. 187 
 188 
Role of the funding source 189 
The funders had no role in study design, data collection, data monitoring, data analysis, data 190 
interpretation, writing of the report, or the decision to submit for publication. The senior author 191 
(SW), the co-principal investigator (TP), and the trial statistician (DH) had full access to all the data in 192 
the study and had final responsibility for the decision to submit for publication. 193 
 194 
RESULTS 195 
Between March 1, 2012, and May 31, 2013, 2119 patients with 3139 lesions were randomly assigned 196 
to receive biodegradable-polymer sirolimus-eluting stents (1063 patients, 1594 lesions) or durable-197 
polymer everolimus-eluting stents (1056 patients, 1545 lesions; figure 1). At 5 years, follow-up data 198 
were available for 994 (94%) patients receiving biodegradable-polymer sirolimus-eluting stents and 199 
for 1014 (96%) patients receiving durable-polymer everolimus-eluting stents (p=0·009). Baseline 200 
clinical, angiographic, and procedural characteristics have been reported previously.5 201 
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The median age of patients was 66·7 years (IQR 33·5–90·2) in the biodegradable-polymer sirolimuse-202 
luting stent group and 66·6 years (38·6–89·1) in the durable-polymer everolimus-eluting stent group. 203 
257 (24%) of 1063 patients treated with biodegradable-polymer sirolimus-eluting stents had 204 
diabetes versus 229 (22%) of 1056 patients treated with durable-polymer everolimus-eluting stents. 205 
More than half of all patients presented with an acute coronary syndrome (577 [54%] patients in the 206 
biodegradable-polymer sirolimus-eluting stent group vs 554 [52%] patients in the durable-polymer 207 
everolimus-eluting stent group); 211 (20%) patients receiving biodegradable polymer sirolimus-208 
eluting stents and 196 (19%) patients receiving durable polymer everolimus-eluting stents had 209 
STEMI. 210 
Adherence to antiplatelet therapy was similar in the two treatment groups at 1 year, 2 years, and 5 211 
years (table 1). At 5 years, 68 (8%) of 849 patients with biodegradable-polymer sirolimus-eluting 212 
stents and 67 (7%) of 896 patients with durable-polymer everolimus-eluting stents were on dual 213 
antiplatelet therapy (p=0·72). 214 
At 5 years, target lesion failure had occurred in 198 patients (cumulative incidence 20·2%) treated 215 
with biodegradable-polymer sirolimus-eluting stents and in 189 (18·8%) patients treated with 216 
durable-polymer everolimus-eluting stents (RR 1·07, 95% CI 0·88–1·31; p=0·487; table 2). Cumulative 217 
incidences of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion 218 
revascularisation were similar in the two treatment groups (figure 2). The findings for target lesion 219 
failure were consistent across various patient subsets in a stratified analysis (figure 3). 220 
The cumulative incidence of definite thrombosis at 5 years was 1·6% in both groups (RR 1·02, 95% CI 221 
0·51–2·05; p=0·950; table 2). Within 1 year after implantation, definite stent thrombosis had 222 
occurred in nine patients (cumulative incidence 0·9%) in the biodegradable-polymer, sirolimus-223 
eluting stent group and in four patients (0·4%) in the durable-polymer, everolimus-eluting stent 224 
group (RR 2·25, 95% CI 0·69–7·32). Between 1 year and 5 years after implantation, seven patients 225 
(0·8%) in the biodegradable-polymer, sirolimus-eluting stent group and 12 (1·3%) in the durable-226 
polymer, everolimus-eluting stent group had definite stent thrombosis (0·61, 0·24–1·54; figure 4). 227 
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There was no difference between groups in the timing of events (pinteraction=0·080; figure 4). 228 
Landmark analyses of clinical outcomes, with the landmark set at 1 year, found no significant 229 
interaction between treatment effect and time (appendix). 230 
At 5 years, a patient-oriented composite outcome consisting of all-cause mortality, any myocardial 231 
infarction, and any revascularisation had occurred in 325 patients (cumulative incidence 32·2%) 232 
treated with biodegradable-polymer sirolimus-eluting stents and in 308 patients (30·3%) treated 233 
with durable-polymer everolimus-eluting stents (RR 1·08, 95% CI 0·92–1·26; p=0·333; table 2; 234 
appendix). All-cause mortality was significantly higher in patients treated with biodegradable-235 
polymer sirolimus-eluting stents than in those treated with durable-polymer everolimus-eluting 236 
stents (14·1% vs 10·3%; RR 1·36, 95% CI 1·06–1·75; p=0·017; table 2). This difference was driven by a 237 
higher incidence of non-cardiovascular death in the biodegradable-polymer sirolimus-eluting stent 238 
group than in the durable-polymer everolimus-eluting stent group, specifically by a two times 239 
increase in the incidence of death secondary to cancer (2·7% [26 patients] vs 1·3% [13 patients]; RR 240 
2·03, 95% CI 1·04–3·95; p=0·037; appendix). The types of malignancy in patients who died from 241 
cancer are shown in the appendix; there was no evidence of a specific type of cancer driving the 242 
difference between groups. 243 
 244 
DISCUSSION 245 
In this large-scale, single blind, randomised trial, the cumulative incidence of target lesion failure 246 
over 5 years of follow-up did not differ between patients treated with biodegradable-polymer 247 
sirolimus-eluting stents and those treated with durable-polymer everolimus-eluting stents, and 248 
there was no significant interaction between treatment effect and time. All-cause mortality was 249 
significantly higher in patients treated with biodegradable-polymer sirolimus-eluting stents than in 250 
those treated with durable-polymer everolimus-eluting stents, which was driven by a difference in 251 
non-cardiovascular death. 252 
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Probably because of the all-comers design of the BIOSCIENCE trial, mortality was more than two 253 
times higher than in the FAME 2 trial,17 and was within the upper range of mortality reported in 254 
other stent trials (appendix). Incidences of target vessel revascularisation and target lesion failure in 255 
our study were similar to those reported at 5 years in the LEADERS and RESOLUTE trials,1,18 and were 256 
considerably higher than those reported in the COMPARE II trial,19 the SORT OUT trials,20–22 and the 257 
Twente trials.23,24 Reported event rates across different trials are affected by a range of factors other 258 
than the stent and need to be interpreted in the context of patient and lesion complexity, medical 259 
treatment, functional testing for ischaemia, endpoint definitions, event reporting, extent of data 260 
monitoring, and event adjudication. We routinely relied on angiographic assessment to establish 261 
lesion severity and used fractional flow reserve only if we were in doubt about lesion severity. 262 
Therefore, the incidence of clinically indicated revascularisation in our study might have been 263 
overestimated. 264 
This study extends the clinical evidence on the newest generation of drug-eluting stents combining 265 
biodegradable polymers with ultrathin-stent platforms. To our knowledge, this study is the first to 266 
assess the longer-term (beyond the degradation time of the polymer) clinical outcomes of an 267 
ultrathin-strut, biodegradable-polymer, sirolimus-eluting stent, in an adequately powered 268 
randomised trial, with the best-in-class durable-polymer everolimus-eluting stent as a comparator. 269 
Evidence from randomised controlled trials comparing Biodegradable polymer sirolimus-eluting 270 
stents with durable-polymer everolimus-eluting stents before full degradation of the polymer have 271 
been conflicting. Some trials (BIOFLOW-II,25 BIOSCIENCE,11 and BIORESORT9) found that 272 
biodegradable sirolimus-eluting stents were non-inferior to durable-polymer drug-eluting stents in 273 
terms of angiographic and composite clinical outcomes. The BIOFLOW-V trial,10 by contrast, found 274 
that a lower proportion of patients treated with biodegradable-polymer sirolimus-eluting stents had 275 
target lesion failure within 1 year of implantation than did those treated with durable-polymer 276 
everolimus-eluting stents. This finding was driven by a difference between groups in the proportion 277 
of patients who had target vessel myocardial infarction, which was defined by both a protocol 278 
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definition26 and an Academic Research Consortium definition15 in the trial, whereas a less sensitive 279 
definition was used in BIOSCIENCE and BIOFLOW-II.11,25 The less sensitive definition of myocardial 280 
infarction in our study could explain the lack of difference in incidence of myocardial infarction 281 
between the two treatment groups. Consistent with the 5 year clinical outcomes of BIOFLOW-II,27 282 
there were no differences in the occurrence of target lesion failure and its individual components of 283 
cardiac death, target vessel myocardial infarction, and clinically indicated target lesion 284 
revacularisation between the stent types in our study. 285 
A meta-analysis28 of ten trials comparing three different types of ultrathin-strut drug-eluting stents 286 
with thicker-strut, second-generation, drug-eluting stents found that ultrathin-strut stents reduced 287 
target lesion failure by 16% compared with thicker-strut stents (RR 0·84, 95% CI 0·72–0·99). This 288 
difference was driven by a lower incidence of myocardial infarction in patients treated with 289 
ultrathin-strut stents than in those treated with thicker-strut stents (0·72, 0·51–1·01). These findings 290 
(which occurred before complete resolution of the polymer) suggest an effect related to strut 291 
thickness; in particular, ultrathin struts might mitigate the compromise of flow in side branches. In 292 
the biodegradable-polymer sirolimus-eluting stent group of our trial, patients with small vessels of 293 
3·0 mm or less were treated with stents of 60 μm strut thickness, whereas those with larger vessels 294 
were treated with stents of 80 μm strut thickness. We therefore did a subgroup analysis by vessel 295 
size using this cutoff, and found no variation in treatment effect. 296 
By contrast with the invariable effect of the ultrathin metallic stent platform, the potential benefit of 297 
the polymer is expected to come into effect after its complete bioresorption, which occurs between 298 
12 months and 24 months after stent implantation. Durable polymers have been shown to sustain a 299 
chronic inflammatory response in histopathologic analyses,29 providing a substrate for incomplete 300 
vascular healing2 and leading to an increased risk of very late stent thrombosis.30 Early generations 301 
of biodegradable-polymer stents based on thick-strut stainless steel platforms were associated with 302 
a decreased risk of very late stent thrombosis compared with durable-polymer drug-eluting 303 
stents.1,30 The 5 year outcomes of the BIOFLOW-II trial did not show a significantly lower incidence of 304 
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stent thrombosis in patients treated with biodegradable-polymer sirolimus-eluting stents than in 305 
those treated with durable-polymer everolimus-eluting stents (0·7% vs 2·8%; hazard ratio 0·25, 95% 306 
CI 0·05–1·39; p=0·088).27 Similarly, long-term data of the BIOSCIENCE trial did not show a difference 307 
in timing of definite stent thrombosis in patients treated with biodegradable-polymer sirolimus-308 
eluting stents between the first year of stent implantation and 1–5 years after stent implantation 309 
(pinteraction=0·080). Of note, adherence to antiplatelet treatment was high in both treatment groups, 310 
and most patients had discontinued treatment with P2Y12 inhibitors beyond 1 year. 311 
A significant difference in all-cause mortality was driven by higher rates of non-cardiovascular death 312 
in patients treated with biodegradable polymer sirolimus-eluting stents than in those treated with 313 
durable polymer everolimus-eluting stents. In particular, patients in the biodegradable polymer 314 
sirolimus-eluting stent group more commonly died from cancer. The difference in all-cause mortality 315 
emerged within 2 years of stent implantation and was not corroborated in the long-term follow-up 316 
of the angiographically powered BIOFLOW-II trial.27,31 Other studies comparing biodegradable-317 
polymer sirolimus-eluting stents with durable-polymer everolimus-eluting stents with follow-up 318 
limited to 1 year did not show a mortality difference between the two types of stents.10,32 Although 319 
the observed difference in this trial might be a chance finding, it warrants further observation during 320 
long-term follow-up of ongoing studies. 321 
Analyses of prespecified subgroups showed a consistent effect of the two stent types across subsets 322 
of patients with diabetes, acute coronary syndromes, and renal failure. A lower incidence of target 323 
lesion failure in patients with STEMI treated with biodegradable sirolimus-eluting stents at 1 year33,34 324 
was not substantiated in the 5-year outcome data. The safety and efficacy of biodegradable polymer 325 
sirolimus-eluting stents compared with durable polymer everolimus-eluting stents in the setting of 326 
STEMI is currently under investigation in the BIOSTEMI trial (NCT02579031).35 327 
Our study has several limitations. First, it was powered to detect non-inferiority with regards to a 328 
primary composite endpoint at 1 year. Potential differences between the two treatment groups with 329 
regards to individual clinical endpoints are hypothesis generating. Event rates for the primary 330 
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endpoint were similar to the original hypothesis,11 and high event rates throughout 5 years 331 
underscore the complexity of the population enrolled in the trial. The medical regimen adhered to 332 
current recommendations and included a substantial proportion of patients treated with novel 333 
P2Y12 inhibitors. Second, follow-up information was missing for 71 patients because of loss to 334 
follow-up, and for 40 patients because of refusal of follow-up. Completeness of follow-up at 5 years 335 
was similar to that in other stent trials that used conventional means of follow-up,36–38 but was lower 336 
than in trials that used ascertainment of outcomes based on health-care registries.20–22 There was a 337 
small but significant difference in completeness of follow-up at 5 years between the two groups. We 338 
are unable to explain this difference and understand its effect on the estimated treatment effects, 339 
but consider it likely to be a chance finding. Third, a significant difference in non-cardiovascular 340 
death was largely driven by an increased incidence of death secondary to cancer in patients in the 341 
biodegradable polymer sirolimus-eluting stent group. A history of cancer was not prospectively 342 
recorded at baseline; hence, we cannot differentiate between death secondary to pre-existing, 343 
recurring, and newly developed cancer in our study population. Fourth, tests for interaction have 344 
low power.39 Finally, although, to our knowledge, our analysis provides the longest available 345 
experience of ultrathin strut biodegradable polymer sirolimus-eluting stents, a difference in very late 346 
stent thrombosis might become apparent only during extended follow-up beyond 5 years. 347 
In conclusion, the final 5 year outcomes of the BIOSCIENCE trial show similar outcomes for ultrathin 348 
strut biodegradable sirolimus-eluting stents and thin strut durable polymer everolimus-eluting stents 349 
with regards to a composite of target lesion failure among patients undergoing percutaneous 350 
coronary intervention for stable coronary artery disease or acute coronary syndromes. Higher 351 
incidences of all-cause and non-cardiovascular mortality in patients treated with biodegradable 352 
polymer sirolimus-eluting stents warrant careful observation in ongoing studies.  353 
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TABLES 522 
Table 1: Medications at discharge and 1 year, 2 years, and 5 years of follow-up 523 
   524 
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Table 2: Clinical outcomes at 5 years of follow-up. 525 
Number of first events (cumulative incidence) are reported. All events were censored after 1825 526 
days. MI=myocardial infarction. TLR=target lesion revascularisation. TVR=target vessel 527 
revascularisation. BARC=Bleeding Academic Research Consortium. *Primary endpoint, defined as the 528 
composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and clinically indicated TLR. 529 
†Includes ischaemic stroke, intracerebral haemorrhagic stroke, and cerebrovascular events with 530 
unclear cause. ‡Defined as the composite of cardiac death, any Q-wave or non-Q-wave MI, and any 531 
TVR. §Defined as all-cause death, any MI, and any repeat revascularisation. 532 
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FIGURES 534 
Figure 1: Trial profile 535 
BP SES=biodegradable-polymer sirolimus-eluting stent. DP EES=durable-polymer everolimus-eluting 536 
stent. BMS=bare metal stent. PCI=percutaneous coronary intervention. CABG=coronary artery 537 
bypass graft. 538 
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Figure 2: Time to event curves for the composite primary endpoint of target lesion failure and its 540 
individual components up to 5 years of follow-up. RR=rate ratio. DP EES=durable-polymer 541 
everolimus-eluting stent. BP SES=biodegradable-polymer sirolimus-eluting stent. (A) Target lesion 542 
failure. (B) Cardiac death. (C) Target vessel myocardial infarction. (D) Clinically indicated target lesion 543 
revascularisation. 544 
 545 
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Figure 3: Stratified analyses of target lesion failure at 5 years across major subgroups. BP 547 
SES=biodegradable-polymer sirolimus-eluting stent. DP EES=durable-polymer everolimus-eluting 548 
stent. STEMI=ST-segment elevation myocardial infarction. PCI=percutaneous coronary intervention. 549 
BMI=body-mass index. *Data in these columns are events/number of patients. 550 
 551 
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Figure 4: Time to event curve for definite stent thrombosis up to 5 years of follow-up. A landmark 553 
was set at 1 year. RR=rate ratio. DP EES=durable-polymer everolimus-eluting stent. BP 554 
SES=biodegradable-polymer sirolimus-eluting stent. 555 
 556 
